Methylene blue therapy in addition to standard treatment for acute-phase septic shock: a pilot randomized controlled trial.

ABSTRACT:

Purpose

Methylene blue (MB) has been used to increase blood pressure in patients with septic shock by acting on guanylate cyclase and nitric oxide synthase.

Objective

To determine whether the administration of MB to patients in the initial phase of septic shock leads to a reduction in the use of vasopressors compared to the Control group.

Methods

This was a 1:1 randomized clinical trial of two groups (MB and Control). Forty-two patients were included in the present study; 23 patients were allocated to the Control group, and 19 were randomized to the MB group. Both groups had access to standard treatment, consisting of fluid replacement, vasopressors, and antibiotic therapy. Patients received a loading dose of MB (3 mg/kg) and maintenance (0.5 mg/kg/h) for 48 h. Vasopr

SUBMITTER: Luis-Silva F 

PROVIDER: S-EPMC11514138 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature